Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amgen (NQ:AMGN)

265.86 -6.19 (-2.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
53 54 Next >
FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?
Don't bank on the FTC winning in its attempt to stop Amgen's buyout of Horizon just yet. 
Via The Motley Fool
Is This Dow Jones Stock a Buy for Income Investors?
This pharmaceutical company is dedicated to maintaining its track record of innovation. 
Via The Motley Fool
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
In a rare move to block a large pharma deal, the U.S. 
Via Benzinga
Why These 2 Large-Cap Stocks Dropped 10%-Plus on Tuesday
Their declines weighed on the broader market. 
Via The Motley Fool
Why Horizon Therapeutics Stock Is Crashing Today
The FTC is reportedly gearing up to block the drugmaker's takeover by Amgen. 
Via The Motley Fool
Looking Into Amgen's Recent Short Interest
Via Benzinga
Analyst Ratings for Amgen
Via Benzinga
What Does Amgen's Debt Look Like?
Via Benzinga
A Look Into Amgen Inc's Price Over Earnings
Via Benzinga
Former SVB CEO Blames Fed & Media Hype For Collapse, FTC Plans Lawsuit to Block Horizon Therapeutics $28B Takeover, Home Depot Lowers Annual Outlook: Today's Top Stories
Benzinga Former SVB Chief Blames Fed, Media Hype For Bank's Devastating Collapse 
Via Benzinga
HZNP Stock Alert: Why Is Horizon Therapeutics Plunging Today
Horizon Therapeutics (HZNP) stock is sinking after the FTC reportedly decided to sue to block its merger with Amgen (AMGN). 
Via InvestorPlace
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way. 
Via Investor's Business Daily
Amgen-Horizon Therapeutics Deal Regulatory Overhang: FTC Plans Lawsuit to Block $28B Takeover
The Federal Trade Commission is expected to file a lawsuit in a bid to block Amgen Inc's (NASDAQ: AMGN) $28 billion takeover of Horizon Therapeutics PLC (NASDAQ: HZNP). 
Via Benzinga
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares 
Via MarketBeat
S&amp;P 500 Futures Slip After Home Depot's Q1 Print: Analyst Says Retest Of October Lows Likely
Via Benzinga
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
From The Law Offices of Frank R. Cruz
Via Business Wire
AMGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:AMGN Investor Notice: Deadline on May 12, 2023 in Lawsuit Against Amgen Inc. Coming Up
San Diego, CA -- (SBWIRE) -- 05/10/2023 -- The Shareholders Foundation announced that a deadline is coming up on May 12, 2023 in the lawsuit filed for certain investors of Amgen Inc. (NASDAQ:AMGN). 
Via SBWire
Why Are TScan Therapeutics Shares Are Shooting Higher Today
Amgen Inc (NASDAQ: AMGN) and TScan Therapeutics Inc (NASDAQ: TCRX) announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recog 
Via Benzinga
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
From TScan Therapeutics, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
AMGN FINAL DEADLINE FRIDAY: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
2 Best Biotech Stocks to Buy Right Now
Buying pharmaceutical companies with all-around drug portfolios and pipelines is the key to success as an investor. 
Via The Motley Fool
AMGN NOTICE: TOP RANKED ROSEN LAW FIRM Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action – AMGN
From The Rosen Law Firm PA
Via GlobeNewswire
2 Magnificent Dividend Stocks to Buy Before the Next Recession
The healthcare sector is a good place to find recession-proof stocks. 
Via The Motley Fool
7 Blue-Chip Stocks to Buy in May 2023
While not the most exciting sector available, rising fears in the market incentivizes the best blue-chip stocks to buy. 
Via InvestorPlace
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.